UNDERWRITING AGREEMENT UROVANT SCIENCES LTD. [●] Shares of Common Shares Underwriting AgreementUnderwriting Agreement • August 30th, 2018 • Urovant Sciences Ltd. • Pharmaceutical preparations • New York
Urovant Sciences Ltd., a company incorporated and organized under the laws of Bermuda (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom J.P Morgan Securities LLC (“J.P. Morgan”), Jefferies LLC (“Jefferies”) and Cowen and Company, LLC (“Cowen”) are acting as representatives (the “Representatives”), an aggregate of [●] common shares, par value $0.00001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [●] common shares of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The common shares of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Common Shares”.
UROVANT SCIENCES LTD. INDEMNITY AGREEMENTIndemnity Agreement • August 30th, 2018 • Urovant Sciences Ltd. • Pharmaceutical preparations
THIS INDEMNITY AGREEMENT (the “Agreement”) is made and entered into as of , 20 between Urovant Science Ltd., an exempted limited company registered in Bermuda (the “Company”), and (“Indemnitee”).
UROVANT SCIENCES, INC. EMPLOYMENT AGREEMENTEmployment Agreement • August 30th, 2018 • Urovant Sciences Ltd. • Pharmaceutical preparations • California
This Employment Agreement (this “Agreement”) is entered into as of September 14, 2017, by and between Keith Katkin (the “Executive”) and Urovant Sciences, Inc. (the “Company”).
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. LICENSE AGREEMENTLicense Agreement • August 30th, 2018 • Urovant Sciences Ltd. • Pharmaceutical preparations • California
THIS LICENSE AGREEMENT (the “Agreement”) is entered into as of August 24, 2018 (the “Effective Date”), by and between ION CHANNEL INNOVATIONS, LLC, a limited liability company organized under the laws of the State of New York and having an address of 23 Agnes Circle, Ardsley, NY 10502, U.S. (“Licensor”), and UROVANT SCIENCES, GMBH, a company organized under the laws of Switzerland and having an address of Viaduktstrasse 8, 4051 Basel, Switzerland (“Licensee”). Licensor and Licensee may be referred to herein individually as a “Party” or collectively as the “Parties”.
